Abstracts tagged "Traps"

Abstract Number: 2905 • 2019 ACR/ARP Annual Meeting
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Allan Klein ¹, David Lin ², Paul Cremer ¹, Saifullah Nasir ³, Sharon Crugnale ⁴, Larisa Collins ⁴, Fang Fang ⁴, Anna Beutler ⁴ and John F Paolini⁴, ¹Cleveland Clinic, Cleveland, OH, ²Minneapolis Heart Institute - Minneapolis, Minneapolis, MN, ³Stat! Cardiologist, Chicago, IL, ⁴Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Recurrent pericarditis (RP) is characterized by the recurrence of pericarditis signs and symptoms after a symptom-free period of ≥4 to 6 weeks and affects…
Abstract Number: 1418 • 2018 ACR/ARHP Annual Meeting
External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab
Isabelle Koné-Paut¹, Maryam Piram², Susanne Benseler³, Jasmin B. Kuemmerle-Deschner⁴, Annette F. Jansson⁵, Itzhak Rosner⁶, Alberto Tommasini⁷, Sara Murias⁸, Omer Karadag⁹, Jeremy Levy¹⁰, Serge Smeets¹¹ and Fabrizio De Benedetti¹², ¹APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ²Pediatrics, APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatrics, University Hospital Tübingen, Tübingen, Germany, ⁵Ludwig Maximilian University, Munich, Germany, ⁶Bnai-Zion Medical Center, Haifa, Israel, ⁷Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy, ⁸Hospital Infantil La Paz, Madrid, Spain, ⁹Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, ¹⁰BIOP, Reinach, AR, Switzerland, ¹¹Novartis Pharma B.V., Arnhem, Netherlands, ¹²IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: AIDAI is a novel and unique, validated patient (pt)-reported assessment tool to evaluate disease activity in familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency…
Abstract Number: 2863 • 2018 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial
Fabrizio De Benedetti¹, Joost Frenkel², Anna Simon³, Jordi Anton⁴, Helen J. Lachmann⁵, Marco Gattorno⁶, Seza Ozen⁷, Isabelle Koné-Paut⁸, Eldad Ben-Chetrit⁹, Magdalena Wozniak¹⁰, Xiaoling Wei¹¹ and Eleni Vritzali¹², ¹IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ²University Medical Center,Utrecht, Utrecht, Netherlands, ³General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ⁵UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁶Pediatric Division, G Gaslini Institute, Genoa, Italy, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, ⁹Rheumatology Unit, Hadassah—Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Novartis Ireland Ltd, Dublin, Ireland, ¹¹China Novartis Institutes for Biomedical Research Co., Ltd, Beijing, China, ¹²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Canakinumab (CAN), a selective, human anti-interleukin (IL)-1β has demonstrated efficacy and safety in patients (pts) with colchicine-resistant familial Mediterranean fever (crFMF), hyper-IgD syndrome (HIDS)/mevalonate…
Abstract Number: 361 • 2017 ACR/ARHP Annual Meeting
Multi-National Observational Patient Diary Study to Assess Disease Burden of Periodic Fever Syndromes (PFS), Including Colchicine-Resistant Familial Mediterranean Fever (crFMF), TNF-Receptor Associated Periodic Syndrome (TRAPS) and Mevalonate Kinase Deficiency (MKD)
Jasmin B. Kuemmerle-Deschner¹, Pierre Quartier², Shai Padeh³, Isabelle Koné-Paut⁴, Veronique Hentgen⁵, Katherine A. Marzan⁶, Fatma Dedeoglu⁷, Helen J. Lachmann⁸, Tilmann Kallinich⁹, Norbert Blank¹⁰, Seza Ozen¹¹, Yelda Bilginer¹², Jonathan S. Hausmann^7,13, Arturo Diaz¹³, Ravi Degun¹⁴, Nina Marinsek¹⁴, Jill Gregson¹⁵, Kathleen G. Lomax¹⁶ and Avi Livneh¹⁷, ¹Pediatrics, University Hospital Tübingen, Tübingen, Germany, ²Necker-Enfants Malades Hospital, Paris, France, ³Sheba Medical Center, Tel-Hashomer, Israel, ⁴Bicêtre Hospital, APHP, Univeristy Paris Sud, Paris, France, ⁵Versailles Hospital, CEREMAI, Le Chesnay, France, ⁶Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ⁷Boston Children's Hospital, Boston, MA, ⁸UCL Division of Medicine, UK National Amyloidosis Centre, London, United Kingdom, ⁹Charité, Humbolt University Medicine Berlin, Berlin, Germany, ¹⁰UniversitätsKlinikum Heidelberg, Heidelberg, Germany, ¹¹Department of Pediatrics, Hacettepe University, Ankara, Turkey, ¹²Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹³Beth Israel Deaconess Medical Center, Boston, MA, ¹⁴Life Sciences, Navigant Consulting, London, United Kingdom, ¹⁵Novartis Pharma AG, Basel, Switzerland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Sheba Medical Center, Ramat-Gan, Israel
Background/Purpose: Periodic fever syndromes (PFS) are a group of autoinflammatory disorders characterized by recurrent bouts of fever and severe localized inflammation which, if not treated,…
Abstract Number: 246 • 2015 ACR/ARHP Annual Meeting
Adult Autoinflammatory Disease Frequency and Our Diagnostic Experience in an Adult Autoinflammatory Clinic
Qingping Yao¹, Felicitas Lacbawan² and Jianbo Li¹, ¹Cleveland Clinic, Cleveland, OH, ²Molecular Genetics Pathology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Autoinflammatory diseases (AIDs), aka, periodic fever syndromes include monogenic diseases, such as familial Mediterranean fever (FMF), cryopyrin-associated periodic disease (CAPS), tumor necrosis factor receptor-associated…
Abstract Number: 251 • 2015 ACR/ARHP Annual Meeting
A New Genetic Mutation in TNF Receptor Associated Periodic Syndrome (TRAPS)
Mark Leith¹, Auleen Millar² and James Burns³, ¹Rheumatology, Antrim Area Hospital,, Antrim, Northern Ireland, ²Rhematology, Antrim area hospital, Antrim, Northern Ireland, ³Antrim area hospital, Antrim, Northern Ireland
Background/Purpose: ,We present the case of a family with a new diagnosis of TRAPs. The father, a 59 year old man with a history of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].